Supernus Pharmaceuticals (SUPN) Convertible Debt (2013 - 2022)

Supernus Pharmaceuticals (SUPN) has 10 years of Convertible Debt data on file, last reported at $400.4 million in Q1 2022.

• Convertible Debt for Q1 2022 came in at $400.4 million, up 9.38% year-over-year; the trailing twelve-month figure through Mar 2022 was $400.4 million (up 9.38% YoY), and the FY2021 annual result was $379.3 million, up 4.84% from the prior year.
• Convertible Debt grew to $400.4 million in Q1 2022 per SUPN's latest filing, from $379.3 million in the prior quarter.
• Over five years, Convertible Debt peaked at $400.4 million in Q1 2022 and troughed at $318.2 million in Q1 2018.
• A 5-year average of $350.9 million and a median of $349.2 million in 2020 frame the typical range for Convertible Debt.
• The sharpest annual moves came in 2018 and 2019: Convertible Debt soared 21769.57% in 2018, then grew 4.74% in 2019.
• A 5-year view of Convertible Debt shows it stood at $329.5 million in 2018, then increased by 4.77% to $345.2 million in 2019, then climbed by 4.8% to $361.8 million in 2020, then gained by 4.84% to $379.3 million in 2021, then climbed by 5.57% to $400.4 million in 2022.
• Business Quant data shows SUPN's Convertible Debt at $400.4 million in Q1 2022, $379.3 million in Q4 2021, and $374.8 million in Q3 2021.